Who Generates Higher Gross Profit? Dr. Reddy's Laboratories Limited or Ligand Pharmaceuticals Incorporated

Dr. Reddy's vs. Ligand: A Gross Profit Comparison

__timestampDr. Reddy's Laboratories LimitedLigand Pharmaceuticals Incorporated
Wednesday, January 1, 20147580100000055402000
Thursday, January 1, 20158540300000066107000
Friday, January 1, 201692281000000103402000
Sunday, January 1, 201778356000000135736000
Monday, January 1, 201876304000000245116000
Tuesday, January 1, 201983430000000108935000
Wednesday, January 1, 202094009000000156000000
Friday, January 1, 2021103077000000214957000
Saturday, January 1, 2022113840000000143418000
Sunday, January 1, 202320297200000096265000
Monday, January 1, 2024163607000000
Loading chart...

Data in motion

A Tale of Two Companies: Gross Profit Showdown

In the competitive world of pharmaceuticals, Dr. Reddy's Laboratories Limited and Ligand Pharmaceuticals Incorporated have been vying for financial supremacy. Over the past decade, Dr. Reddy's has consistently outperformed Ligand in terms of gross profit. From 2014 to 2023, Dr. Reddy's gross profit surged by over 167%, peaking in 2023 with a remarkable 202 billion. In contrast, Ligand's highest recorded gross profit was a modest 245 million in 2018, highlighting a stark difference in scale.

Key Insights

  • Dr. Reddy's Dominance: By 2023, Dr. Reddy's gross profit was approximately 830 times that of Ligand's.
  • Ligand's Growth: Despite being overshadowed, Ligand showed a notable increase of 344% from 2014 to 2018.

This data underscores the diverse strategies and market positions of these two pharmaceutical giants, offering a fascinating glimpse into their financial trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025